Danske Bank A S Makes New Investment in Natera, Inc. $NTRA

Key Points

• Danske Bank initiated a position in Natera, purchasing 61,302 shares valued at approximately $16.64 million. Institutional investors now own 99.90% of the company’s stock.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above analyst expectations, while its adjusted loss of $0.47 per share narrowly beat estimates.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $319.38; shares recently traded at $324.84 after reaching a 52-week high of $333.56.

Danske Bank A S purchased a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 61,302 shares of the medical research company's stock, valued at approximately $16,640,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Horizon Investments LLC lifted its position in Natera by 22.0% in the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company's stock worth $56,000 after purchasing an additional 44 shares during the period. Parallel Advisors LLC boosted its stake in Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock valued at $181,000 after purchasing an additional 47 shares in the last quarter. First Horizon Corp increased its position in shares of Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company's stock valued at $196,000 after purchasing an additional 51 shares during the period. Siemens Fonds Invest GmbH increased its position in shares of Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company's stock valued at $290,000 after purchasing an additional 54 shares during the period. Finally, Alamea Verwaltungs GmbH raised its stake in shares of Natera by 2.9% in the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company's stock worth $515,000 after buying an additional 62 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Down 0.1%

Shares of NASDAQ NTRA opened at $324.84 on Friday. The stock's fifty day simple moving average is $271.84 and its 200 day simple moving average is $228.67. The stock has a market capitalization of $46.82 billion, a price-to-earnings ratio of -238.85 and a beta of 1.51. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $333.56.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same quarter last year, the firm posted ($0.74) earnings per share. Natera's revenue was up 37.7% compared to the same quarter last year. As a group, analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares of the company's stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the company's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total value of $79,057.05. Following the completion of the sale, the insider directly owned 183,774 shares in the company, valued at $49,249,594.26. This trade represents a 0.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 181,045 shares of company stock worth $41,330,968 in the last 90 days. Company insiders own 5.05% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wells Fargo & Company raised their target price on Natera from $220.00 to $284.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. Guggenheim boosted their price target on shares of Natera from $290.00 to $360.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a report on Friday, July 17th. Piper Sandler raised their price objective on shares of Natera from $249.00 to $363.50 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $355.00 price objective on shares of Natera in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source